<DOC>
	<DOCNO>NCT02865369</DOCNO>
	<brief_summary>A study regression liver fibrosis assess transient elastography Daclatasvir Asunaprevir combine treatment advanced fibrotic/cirrhotic patient chronic hepatitis C genotype 1b Infection</brief_summary>
	<brief_title>Regression Liver Fibrosis After Daclatasvir Asunaprevir Treatment</brief_title>
	<detailed_description>The measurement liver stiffness transient elastography ( TE ) show correlate hepatic fibrosis stage considerable accuracy diagnosis cirrhosis patient chronic hepatitis C. Previous study report liver stiffness significantly reduce SVR patient pegylated interferon ( IFN ) ribavirin treatment . Once patient achieve sustain virological response ( SVR ) , resultingly low liver stiffness score baseline value , believe well long-term outcome due improvement liver fibrosis . Daclatasvir ( DCV ) Asunaprevir ( ASV ) combine treatment show great SVR rate CHC compare IFN base therapy . The investigator hypothesize DCV ASV combine treatment may achieve improvement liver stiffness measure TE favorable clinical outcome patient advance liver fibrosis . The investigator also compare change fibrosis stage assess TE study subject treat DAA agent observational period .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Chronically infect Hepatitis C virus genotype 1b HCV RNA ≥ 10^4 IU/mL ( 10,000 IU/mL ) Chronic Hepatitis C advance fibrosis cirrhosis ( define ≥F3 , ≥8 kilopascals ) Treatmentnaïve previously fail treatment peginterferon alfa ribavirin Women childbearing potential ( WOCBP ) men , use effective method birth control Patients baseline key NS5A RAVs ( Y93 and/or L31 ) Estimated GFR &lt; 30mL/min without hemodialysis Alanine aminotransferase ( ALT ) &gt; 100 IU/L Coinfection hepatitis virus human immunodeficiency virus A daily alcohol intake &gt; 30 g Decompensated liver disease hepatocellular carcinoma , liver organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>chronic hepatitis C</keyword>
	<keyword>Daclatasvir</keyword>
	<keyword>Asunaprevir</keyword>
	<keyword>fibrosis</keyword>
	<keyword>transient elastography</keyword>
</DOC>